WooGene B&G Co., Ltd (KOSDAQ:018620)
South Korea
· Delayed Price · Currency is KRW 693.00
-21.00 (-2.94%)
At close: Mar 9, 2026
WooGene B&G Revenue
WooGene B&G had revenue of 13.22B KRW in the quarter ending September 30, 2025, with 13.07% growth. This brings the company's revenue in the last twelve months to 54.77B, down -6.59% year-over-year. In the year 2024, WooGene B&G had annual revenue of 55.68B, down -3.87%.
Revenue (ttm)
54.77B
Revenue Growth
-6.59%
P/S Ratio
0.37
Revenue / Employee
553.27M
Employees
92
Market Cap
20.02B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 55.68B | -2.24B | -3.87% |
| Dec 31, 2023 | 57.92B | 14.22B | 32.53% |
| Dec 31, 2022 | 43.70B | 4.36B | 11.07% |
| Dec 31, 2021 | 39.35B | -176.99M | -0.45% |
| Dec 31, 2020 | 39.52B | 9.87B | 33.28% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2012 | Pro | Pro | Pro |
| Dec 31, 2011 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Union Korea Pharm | 33.83B |
| BIFIDO | 18.65B |
| Kwangdong Healthbio | 38.10B |
| Daesung Microbiological Labs. | 25.86B |
| ChoA Pharmaceutical Co., LTD. | 60.50B |
| Pharmsville | 13.36B |
| Future Medicine | 1.00B |
| Hurum | 95.37B |